Inventiva’s At-The-Market Offering

Davis Polk advised the sales agent on the deal.

Inventiva S.A., a clinical-stage biotechnological company, announced the implementation of an At-The-Market (“ATM”) program allowing the Company to issue and sell, including with unsolicited investors who have expressed an interest, ordinary shares in the form of American Depositary Shares (“ADS”), each ADS representing one ordinary share of Inventiva, with aggregate gross sales proceeds of up to $100,000,000 from time to time, pursuant to the terms of a sale agreement with Jefferies LLC (“Jefferies”), acting as sales agent. 

Inventiva is focused on the development of oral small molecule therapies for the treatment of NASH, MPS and other diseases with significant unmet medical need. 

The Davis Polk capital markets team included partners Deanna L. Kirkpatrick (Picture) and Yasin Keshvargar and associates Jeannette Safi and Courtney Y. Sohn. Partner Jacques Naquet-Radiguet and associates Stéphane Daniel and Johann Jabes provided advice on matters of French law. Partner David R. Bauer and associate S. Dream Montgomery provided intellectual property advice. The tax team included counsel Alon Gurfinkel. 

Involved fees earner: David Bauer – Davis Polk & Wardwell; Stéphane Daniel – Davis Polk & Wardwell; Alon Gurfinkel – Davis Polk & Wardwell; Johann Jabes – Davis Polk & Wardwell; Yasin Keshvargar – Davis Polk & Wardwell; Deanna Kirkpatrick – Davis Polk & Wardwell; S. Dream Montgomery – Davis Polk & Wardwell; Jacques Naquet-Radiguet – Davis Polk & Wardwell; Jeannette Safi – Davis Polk & Wardwell; Courtney Sohn – Davis Polk & Wardwell;

Law Firms: Davis Polk & Wardwell;

Clients: Jefferies;

Author: Alejandro Girola